Leukemia Research

, volume 28 , issue 4 , pages 415-419

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

Jana Moravcová ¹

Václava Zmeková ¹

Hana Klamová ¹

Jaroslava Voglová ²

Edgar Faber ³

Kyra Michalová ¹

Jana Rabasová ²

M. Jarosova ³

Hide authors affiliations Show authors affiliations: 3 affiliations

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Praha 2, Czech Republic |

Department of Hematology, University Hospital, Hradec Králové, Czech Republic |

Hemato-oncology Department, University Hospital, Olomouc, Czech Republic |

Publication type: Journal Article

Publication date: 2004-04-01

Elsevier

Leukemia Research

scimago Q2

wos Q3

SJR: 0.784

CiteScore: 3.7

Impact factor: 2.2

ISSN: 01452126, 18735835

DOI: 10.1016/j.leukres.2003.08.002

Copy DOI

PubMed ID: 15109543

Cancer Research

Oncology

Hematology

Abstract

Kinetics of BCR-ABL transcript levels were determined in 19 patients with chronic myeloid leukemia (CML) treated with imatinib for chronic (CP) or accelerated phase (AP). Patients could be divided into three groups with: (1) a sharp and sustained decrease in BCR-ABL transcript level reaching 0.1-0.002% (only CP); (2) an early BCR-ABL overexpression up to 2500% (only AP); and (3) a stable trend with BCR-ABL values between 10 and 100% (CP, AP). In group 1, relapses were not developed within the follow-up; in group 2, patients progressed to blast crisis; in group 3, BCR-ABL overexpression appeared after 12 months in some patients and disease relapses were found 2-16 weeks later. It is summarized that BCR-ABL transcript kinetics clearly characterize responses to imatinib treatment and are highly predictive for disease progression.

Found

Top-30

Journals

	1 2 3 4
Leukemia Research	Leukemia Research, 4, 26.67% Leukemia Research 4 publications, 26.67%
Leukemia	Leukemia, 2, 13.33% Leukemia 2 publications, 13.33%
Hematology	Hematology, 2, 13.33% Hematology 2 publications, 13.33%
Blood	Blood, 2, 13.33% Blood 2 publications, 13.33%
Oncotarget	Oncotarget, 1, 6.67% Oncotarget 1 publication, 6.67%
Experimental Hematology	Experimental Hematology, 1, 6.67% Experimental Hematology 1 publication, 6.67%
Biochemical and Biophysical Research Communications	Biochemical and Biophysical Research Communications, 1, 6.67% Biochemical and Biophysical Research Communications 1 publication, 6.67%
Biopharmaceutics and Drug Disposition	Biopharmaceutics and Drug Disposition, 1, 6.67% Biopharmaceutics and Drug Disposition 1 publication, 6.67%
Biomacromolecules	Biomacromolecules, 1, 6.67% Biomacromolecules 1 publication, 6.67%
	1 2 3 4

Publishers

	1 2 3 4 5 6
Elsevier	Elsevier, 6, 40% Elsevier 6 publications, 40%
Springer Nature	Springer Nature, 2, 13.33% Springer Nature 2 publications, 13.33%
Taylor & Francis	Taylor & Francis, 2, 13.33% Taylor & Francis 2 publications, 13.33%
American Society of Hematology	American Society of Hematology, 2, 13.33% American Society of Hematology 2 publications, 13.33%
Impact Journals	Impact Journals, 1, 6.67% Impact Journals 1 publication, 6.67%
Wiley	Wiley, 1, 6.67% Wiley 1 publication, 6.67%
American Chemical Society (ACS)	American Chemical Society (ACS), 1, 6.67% American Chemical Society (ACS) 1 publication, 6.67%
	1 2 3 4 5 6

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Moravcová J. et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase // Leukemia Research. 2004. Vol. 28. No. 4. pp. 415-419.

GOST all authors (up to 50) Copy

Moravcová J., Zmeková V., Klamová H., Voglová J., Faber E., Michalová K., Rabasová J., Jarosova M. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase // Leukemia Research. 2004. Vol. 28. No. 4. pp. 415-419.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.leukres.2003.08.002

UR - https://doi.org/10.1016/j.leukres.2003.08.002

TI - Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

T2 - Leukemia Research

AU - Moravcová, Jana

AU - Zmeková, Václava

AU - Klamová, Hana

AU - Voglová, Jaroslava

AU - Faber, Edgar

AU - Michalová, Kyra

AU - Rabasová, Jana

AU - Jarosova, M.

PY - 2004

DA - 2004/04/01

PB - Elsevier

SP - 415-419

IS - 4

VL - 28

PMID - 15109543

SN - 0145-2126

SN - 1873-5835

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2004_Moravcová,

author = {Jana Moravcová and Václava Zmeková and Hana Klamová and Jaroslava Voglová and Edgar Faber and Kyra Michalová and Jana Rabasová and M. Jarosova},

title = {Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase},

journal = {Leukemia Research},

year = {2004},

volume = {28},

publisher = {Elsevier},

month = {apr},

url = {https://doi.org/10.1016/j.leukres.2003.08.002},

number = {4},

pages = {415--419},

doi = {10.1016/j.leukres.2003.08.002}

}

MLA

Cite this

MLA Copy

Moravcová, Jana, et al. “Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.” Leukemia Research, vol. 28, no. 4, Apr. 2004, pp. 415-419. https://doi.org/10.1016/j.leukres.2003.08.002.

Publisher

Elsevier

Journal

Leukemia Research

scimago Q2

wos Q3

SJR

0.784

CiteScore

3.7

Impact factor

2.2

ISSN

01452126 (Print)

18735835 (Electronic)